Neurological & CognitiveLimited ResearchInvestigational (Phase 2)C

ARA-290

Cibinetide

Last reviewed . First published . By the PeptIQ team.

Educational and observational reference only. Not medical advice. Community charts may use modeled aggregates when live snapshots are unavailable.

Studies cited
4
Research grade
C
Experience
70

Overall check-ins

Activity
100

Trackers & reports

Typical Dose

Varies by protocol

Route

Injectable

Cycle

Protocol-dependent

Storage

2–8°C Refrigerated

What is ARA-290?

Non-erythropoietic peptide studied for neuropathic and inflammatory indications.

Research Indications

Cognitive FunctionEffective

Research suggests improvements in memory, focus, and cognitive processing

NeuroprotectionModerate

May protect neurons from oxidative stress and inflammatory damage

Mood & AnxietyModerate

Some studies report anxiolytic and mood-stabilizing effects

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Starting DoseLow doseOnce dailyIntranasal or Injectable
Standard DoseStandardOnce dailyIntranasal or Injectable

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

Stimulants (Modafinil, Adderall)Caution
MAOIs / SSRIsMonitor
RacetamsCaution
NAD+Compatible
BPC-157Compatible

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove ARA-290 vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Subtle mood and focus improvements may begin. Sleep quality often improves early.

Week 2–4

Increased mental clarity, word recall, and reduced brain fog reported by many.

Week 4–8

Consistent cognitive improvements. Better stress response and working memory.

Week 8+

Sustained cognitive and neurological benefits. Effects may persist post-cycle.

Side Effects & Safety

  • Headache, particularly at initiation
  • Mild anxiety or restlessness with some compounds
  • Nasal irritation (intranasal administration)
  • Sleep disturbance if dosed too close to bedtime
  • Rare: Mood changes or emotional lability

FDA Status & Regulatory Info

Investigational (Phase 2)

Non-erythropoietic peptide studied for neuropathic and inflammatory indications.

Rx Required: No
503A Ban: No
Telehealth: N/A
Full FDA Status Tracker

Frequently Asked Questions

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

What 2,396 users report

Observational self-reports (modeled when live data is unavailable). Not clinical outcomes.

2396 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 50% · Mixed 34% · Unfavorable overall 16%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
79
Focus
110
Sleep quality
159
Lean mass
165
Joint comfort
98

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
175
Nausea
189
Water retention
124
Appetite loss
161
Injection site reaction
98

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 25–600 mcg

25–50
8
50–100
16
100–200
19
200–400
14
400–600
8

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing40stacking13side effects16ara-29029

How repeat users are trending

Among repeat reporters, 60% said they felt similar to their last entry, 30% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 31 days · Based on 527 repeat reporters

Share Your Experience

Rate ARA-290 in the PeptIQ app and help the community make informed decisions.

Research References (3)

Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.

  1. PubMed

    ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves neuropathic symptoms in patients with sarcoidosis

    Dahan A, Dunne A, Swartjes M, et al. Mol Med. 2013

    Source
    Wiki study page →
  2. PubMed

    ARA 290 for treatment of small fiber neuropathy in sarcoidosis

    van Velzen M, Heij L, Niesters M, et al. Expert opinion on investigational drugs. 2014

    Source
    Wiki study page →
  3. PubMed

    The time to develop treatments for diabetic neuropathy

    Rendell MS. Expert opinion on investigational drugs. 2021

    Source
    Wiki study page →

Wiki tools

Observational indexes and compare views for ARA-290.

Educational information only

This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

PeptIQ app

Log your ARA-290 protocol in PeptIQ

Turn this ARA-290 guide into a living protocol — doses, vials, and history in one place.

Track ARA-290Open web app

iOS, Android, and web

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Quick Facts

Route
Injectable
Availability
Varies
Rx Required
No
503A Ban
No
Browse peptide education

Talk with a clinician

PeptIQ is education only. We do not sell peptides or list vendors. Discuss ARA-290 with a licensed healthcare provider — not medical advice, not a prescription.

Download PeptIQ

Wiki tools

Observational indexes and compare views for ARA-290.